- Denali Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights
- Denali Therapeutics Announces Completion of Enrollment for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial
- Denali Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
- Denali Therapeutics Announces $500 million Private Placement Equity Financing
- Denali Therapeutics Announces New Data and Expansion of Its Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapy Programs at WORLDSymposium™
- Denali Therapeutics Announces Presentations on Its Investigational Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapies at the Upcoming 2024 WORLDSymposium™
- Denali Therapeutics Announces Key Anticipated 2024 Milestones and Priorities to Further Advance Its Therapeutics Portfolio for Neurodegeneration and Lysosomal Storage Diseases
- Denali Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights
- Denali Therapeutics Announces New Interim Data from Phase 1/2 Study of DNL310 (ETV:IDS) in MPS II (Hunter Syndrome) at SSIEM 2023
- Denali Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights
More ▼
Key statistics
On Thursday, Denali Therapeutics Inc (4DN:BER) closed at 17.53, 27.86% above the 52 week low of 13.71 set on Apr 25, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 18.55 |
---|---|
High | 18.56 |
Low | 17.53 |
Bid | 17.28 |
Offer | 18.37 |
Previous close | 18.51 |
Average volume | 33.89 |
---|---|
Shares outstanding | 142.61m |
Free float | 123.10m |
P/E (TTM) | -- |
Market cap | 2.86bn USD |
EPS (TTM) | -0.9661 USD |
Data delayed at least 15 minutes, as of May 23 2024 19:30 BST.
More ▼